Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia
International Journal of Hematology, 08/20/2012
Takami A et al. – The findings suggest that long–term treatment with low–dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.



